IBD & IBS
Strong lab evidence for anti-inflammatory action, but human trials are few and small.
Digestive Emerging
What the research says
The gut is full of cannabinoid receptors, and animal models of IBD respond impressively to cannabinoids — especially the anti-inflammatory CB2 pathway. That preclinical promise, plus widespread patient reports of symptom relief, drives a lot of interest.
The human data is the disappointment: a few small trials of CBD in active Crohn's disease failed to show clear superiority over placebo (though they were underpowered and used CBD alone). THC-containing products are reported to help symptoms like cramping, pain, and appetite even when they don't change inflammation on scope.
The honest caveats
Two big cautions: (1) CHS — cannabis hyperemesis syndrome — is a real, paradoxical condition of cyclic vomiting in some heavy users, so cannabis is not a safe 'free pass' for GI issues. (2) Relief of symptoms does not mean the disease is treated; inflammation can progress silently. Anyone with IBD should stay under a gastroenterologist's care.
Compounds to explore
These are the compounds — terpenes and cannabinoids — that the research connects to this condition. They are starting points for reading a COA or choosing a product, not prescriptions. Each has its own guide with more detail.
Cannabinoid CBD Anti-inflammatory cannabinoid studied in Crohn's disease. Cannabinoid THC May help with cramping and appetite; the psychoactive effects can be unwanted. Terpene beta-caryophyllene Direct CB2 anti-inflammatory activity — relevant to gut inflammation. Cannabinoid CBG Strong CB2-mediated anti-inflammatory and immunoregulatory effects; shown to help patients with IBD in early research.